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Plenary session highlights
The Judith Stitt Best Abstract Award recipients are selected 
through the ABS’s meticulous scientific committee review 
process and the recipients’ abstracts are presented in the 
Annual Meeting’s plenary session. The 2017 Annual Meeting 
saw hundreds of abstract submissions, and four abstracts 
stood out to receive the award named for and established 
in the memory of Dr. Judith Stitt, who was very active in 
the ABS. The first recipient, Nicolae et al. presented the 
Evaluation of a Machine-Learning Algorithm for Treatment 
Planning in Prostate Low-Dose-Rate (LDR) Brachytherapy 
with initial findings suggesting that their prototype 
algorithm demonstrates the capability to generate LDR 
prostate brachytherapy pre-operative treatment plans (1). 
The authors found that their plans are comparable to the 
quality of plans which were simultaneously created by 
experts trained in brachytherapy (Figure 1) (1). The authors 
suggested that in looking to the future, automated planning 
algorithms for brachytherapy will improve uniformity of 
plans, reduce planning time, and decrease errors and the 
number of staff resources needed for brachytherapy (1). 
Researchers working on NRG/RTOG 0526, a prospective 
multicenter trial reporting on the outcomes of salvage LDR 
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brachytherapy following External Beam Radiation Therapy 
(EBRT) received the second award and presented initial 
findings in A Prospective Phase II Trial of Trans-Perineal 
Ultra-Sound-Guided Brachytherapy for Locally Recurrent 
Prostate Cancer After External Beam Radiotherapy (NRG/
RTOG 0526) (2). The investigators discussed that the study’s 
rate of late grade 3 adverse events was reported at 14%, 
without any grade 4–5 events and were comparable to 
previous study findings (2). The importance of implant dose 
as a predictive factor of late adverse events was discussed as 
well as the need for meticulous planning and technique to 
limit the final delivered dose (2). Clinical outcomes of this 
study will be reported when minimum 5-year follow-up 
data is available (2).
The third award recipient, Sparks et al., presented 
their  f indings regarding long-term outcomes for 
patients with choroidal melanoma treated with I125 eye 
plaque brachytherapy (3). The group’s institutional 
experience found that patients treated with I125 eye plaque 
brachytherapy had similar local control and metastases rates 
and had better visual preservation in comparison to those 
outcomes reported by Collaborative Ocular Melanoma 
Studies (3). And finally, in the fourth award recipient’s 
presentation investigators discussed that the incomplete 
PET/CT response rate in cervical cancer patients was 
documented in 17% of centrally reviewed patients following 
MRI based brachytherapy for cervical cancer (4). Results 
showed that the false positive rate of PET-IR was 74%, and 
integration of functional MRI helped further differentiate 
true positives from false positives (4). Kalash et al. concluded 
as part of their research that the value of functional MRI 
requires further validation in a prospective large dataset, 
as this imaging modality may allow for earlier intervention 
and salvage treatment in those with PET-IR (4).
The Judith Stitt Best Abstract Award recipients 
highlight the clinical advancements of brachytherapy 
across many disease sites as well as the research that at this 
time is focusing on advanced technologies. Utilization of 
advanced technologies such as planning algorithms and 
MRI technologies will increase the precision of treatment 
delivery, subsequently improving outcomes and decreasing 
toxicities for patients in the long term.
Advances in prostate brachytherapy: it’s role in 
the treatment course and MRI integration
Advances in prostate brachytherapy in recent years have 
focused on its utilization in combination with EBRT for 
patients with high risk disease and the utilization of MRI 
guided therapies for more targeted anatomical delineation 
and improved outcomes. Results of the study entitled Lack of 
Benefit Associated with External Beam Radiotherapy in Addition 
to Brachytherapy for Intermediate- to High-Risk Prostate Cancer 
suggest, when adjusting for patient-specific factors, that 
eligible patients with intermediate-risk or high-risk prostate 
cancer treated with brachytherapy might not benefit from 
the additional use of EBRT in their treatment course (5). 
The findings of this study were consistent with the recent 
randomized trial showing that men with relatively favorable 
intermediate-risk disease can be treated with brachytherapy 
alone (5). Studies such as these provide a framework for 
future prospective trials evaluating brachytherapy with 
ADT for patients with unfavorable-intermediate or high-
risk disease, according to the researchers (5). 
Figure 1 Demonstration of axial isodose distributions for a single patient showing (A) the ML plan, (B) the expert BT plan and (C) a generic 
optimization algorithm plan (1). 
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The Annual Meeting also featured the work of Pearse 
et al., who investigated and found the use of real time 
transrectal ultrasound-based planning for high dose-
rate brachytherapy boost, using a 15 Gy implant, for 
intermediate and high-risk prostate cancer is associated 
with favorable outcomes (Figure 2) (6). The group’s findings 
are in line with the results of their previous study for 
intermediate risk patients (6). All et al. sought to determine 
that feasibility and outcomes of MRI-Based planning for 
high dose rate (HDR) brachytherapy for prostate cancer (7). 
The group’s research suggested that MRI-based treatment 
planning is feasible for the delivery of HDR brachytherapy 
for prostate cancer (7). The group’s plans met stringent 
dosimetric criteria with more accurate target and normal 
tissue definition (Figure 3) (7). Given these results, the 
group’s institution has adopted MRI as their standard 
imaging modality for HDR brachytherapy for prostate 
cancer (7). Although an opportunity remains for improved 
efficiency in their process, the authors concluded that 
patient treatment time is reasonable utilizing MRI based 
planning (7).
Poulin et al. sought to show validation of MRI to 
ultrasound (US) registration for focal HDR prostate 
brachytherapy (8). The group concluded that deformable 
registration was significantly more accurate than rigid 
registration for brachytherapy MRI-US fusion (Figure 4) (8). 
Using both Hausdorff distance and TRE for common 
points, the study demonstrated that the deformable 
registration is sufficiently accurate and precise for use 
in focal HDR prostate brachytherapy (8). Sanders et al. 
argued that being able to perform accurate dosimetry using 
MRI images without endorectal coil is important for more 
widespread adoption of MRI in prostate brachytherapy (9). 
Their results, presented in the abstract entitled MRI-
Based Prostate Brachytherapy - Imaging with and without an 
Endorectal Coil for Post-Implant Quality Assurance, indicated 
that optimization in pulse sequences and scan protocols 
shows promise in achieving images of sufficient quality to 
visualize both anatomy and MRI markers adjacent to the 
radioactive seeds in prostate brachytherapy (Figure 5) (9). 
The researchers suggested that additional technical 
development such as higher field strength, better pulse 
sequences and image reconstruction algorithms, and 
optimized marker technologies may further improve 
image quality in the future (9). Martin et al. researched the 
utilization of automated detection of post-implant prostate 
brachytherapy seeds on MRI (10). The group found 
that automated detection is feasible, with good accuracy, 
enabling MRI only post-implant dosimetry (10). According 
to the findings, the utilization of this reduces the number of 
Figure 2 Probability of biochemical disease-free survival following high dose-rate (HDR) brachytherapy boost delivered as a single fraction 
with real-time transrectal ultrasound (TRUS) guidance (6).
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brachytherapy seeds which need to be identified manually 
and suggested that their continued research will work to 
refine the algorithm to focus on reduced computational 
time and improved seed detection in the future (10).
The utilization of MRI technologies in the planning and 
delivery of prostate brachytherapy is a technique which 
has grown in investigational and clinical use over the past 
decade. Although changes in clinical practice and training are 
required to utilize MRI for planning and delivery of prostate 
brachytherapy research reported at the Annual Meeting 
shows promise that its utilization can decrease toxicity to 
surrounding tissues and organs at risk and that it has the 
ability to more accurately delineate disease and surrounding 
anatomy for more accurate dose distribution. The utilization 
of MRI has the potential to better delineate both prostate 
anatomy and disease, increasing the rate of positive clinical 
outcomes and decreasing side effects for patients.
Advances in prostate brachytherapy: outcomes 
and toxicities
In addition to research focused on MRI technologies, 
significant research in brachytherapy has focused on 
improved outcomes and reduced toxicities. The study 
completed and presented by Yorozu et al., Predictive 
Factors of Long-Term Rectal Toxicity Following I-125 Prostate 
Brachytherapy with or without External Beam Radiotherapy, 
found that prostate brachytherapy utilizing I-125 seeds, 
especially when used as monotherapy, is well tolerated (11). 
The researchers concluded that rectal dosimetry is relevant 
to long-term rectal toxicity following brachytherapy in both 
the monotherapy and boost setting following EBRT (11). 
The group’s results showed with rectal dose constraints that 
are both proper and achievable, EBRT yielded less toxicity 
when used in combination with brachytherapy (11).
Hegde et al. reported on a study of men with high-
risk prostate cancer treated with EBRT plus an HDR 
brachytherapy boost and found that MRI evidence of 
seminal vesicle invasion predicted for biochemical failure 
and that pre-treatment clinical and biopsy variables were 
not predictive, as commonly believed (12). The group 
concluded that pre-treatment multiparametric MRI 
can be useful for identifying men who are at higher risk 
for biochemical failure following a EBRT and HDR 
brachytherapy boost treatment (12). Vigneault et al. 
researched the different HDR brachytherapy boost 
treatment courses at their individual institution and found 
that an increase in BED is correlated with an improvement 
of biochemical control, as defined in their research a nPSA 
<0.4 ng/mL (13). The group found that improvement in 
biochemical control, however, is also associated with slight, 
but clinically acceptable, increase in urinary toxicity (13). 
Morris et al. found that using a Surgical PSA-Threshold 
(>0.2 ng/mL) of biochemical failure in the ASCENDE-RT 
population greatly increased the number and percentage of 
biochemical relapse events for the subset of trial patients 
that received an external beam boost (14). However, 
the group found that the application of this threshold 
had little effect on the subset of patients who received a 
brachytherapy boost (14).
Morton et al. investigated the use of one versus two 
fractions of Prostate HDR monotherapy and presented 
short term follow up data which suggested that higher PSA 
values and higher local recurrence rates were found in the 
Figure 3 Pre-treatment DVH goals to the target were: D90 ≥95%, V90 ≥95%, V100 ≥90%, V150 ≤30%, V200 ≤15%. DVH goals to normal 
structures were: urethra D.01cc ≤115%, bladder D1cc ≤75%, rectum D1cc ≤75%, neurovascular bundle D0.1cc ≤100%, penile bulb D1cc ≤100% (7). 
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Figure 4 A representative registration between MRI (blue) and US (red) contours for (A) rigid and (B) deformable registration (8). 
A
B
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single fraction arm (15). The group suggested that 19 Gy 
does not appear to be biologically equivalent to 27 Gy in 
2 fractions and suggested that a single 19 Gy fraction should 
be used with caution as monotherapy (Figure 6) (15).
Researchers who presented data on prostate brachytherapy 
treatment ,  outcome and tox ic i ty  f indings  at  the 
2017 Annual Meeting relayed the importance of dosimetry 
in predicting long-term toxicity and BED calculations 
following brachytherapy as well as predictive factors for 
outcomes and the importance of defining failure and relapse 
thresholds. Prostate brachytherapy researchers continue to 
work to improve the efficacy, outcomes and toxicities of this 
Figure 5 Comparison of the MR images acquired for the same patient with (A) and without (B) the ERC (9). 
A B
Figure 6 Median PSA values for high dose-rate (HDR) brachytherapy monotherapy as either 19 Gy ×1 or 13.5 Gy ×2 in early stage prostate 
cancer (15). 
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treatment modality to better treat patients with this disease.
Brachytherapy’s socioeconomic efficacy 
highlights
Socioeconomic factors are crucial considerations in the 
implementation, utilization and future of brachytherapy 
across the globe. In recent years, the research on 
socioeconomic factors impacting the utilization of 
brachytherapy have focused on program implementation 
considerations as well as the socioeconomic status and 
demographics of patient populations and the country of 
implementation.
HDR brachytherapy for cervical cancer has been 
successfully established in Nicaragua, a developing country 
with limited resources and a high burden of disease per 
the presentation by Nurkic et al. (16). The center achieved 
a program through a dedicated HDR room apart from 
established EBRT rooms and through implementation of 
a multi-phase treatment plan and delivery workflow (16). 
Although the group reported that challenges remain in 
regards to patient access, dated technology and software, 
as well as equipment maintenance, they are comfortable 
reporting on the successful implementation of the program 
in the low-middle income country (16). This successful 
example of implementation of an HDR program in a 
resource-limited environment could serve to guide other 
countries in similar circumstances in the future (16). The 
authors of the abstract entitled “Starting a Prostate HDR 
Program in a Young Cancer Center - 1st Year Experience” 
reported that the implementation of a new HDR prostate 
brachytherapy program should be approached as a continual 
improvement process (17). The study group found that 
the planning of details and communication between all 
members of the multidisciplinary team is imperative 
for successful protocol implementation (17). Using an 
iterative validation process approach was fundamental in 
improving the efficacy and made the group able to improve 
both quality and efficiency in the process according to 
researchers (17).
The authors of “Social and Racial Divides in the Utilization 
of Brachytherapy for Common Malignancies” utilized a large, 
population-based analysis to show that it is evident that 
disparities in care utilizing brachytherapy exist because of 
both social and racial factors (18). The researchers suggested 
that these gaps need to be further examined and remedied to 
provide standard of care therapy to all patients (18).
Vega et al. researched the factors which are associated 
with a willingness of organizations to invest in a HDR 
program utilizing Co-60 and found that decision makers 
in RT equipment acquisition had low willingness to 
invest in shielding should an HDR source more cost-
effective than Ir-192 become available (19). Other 
factors influential included ABS membership and having 
attended a national conference for brachytherapy, and 
centers with a higher number of attending physicians was 
associated with higher willingness to invest (19). The 
group concluded that given the results, larger centers 
with greater exposure to brachytherapy may be more 
likely to adopt a new HDR source in the future (19). 
The group argued that centers currently shielded for 
Co-60 may pursue the utilization of this source, but that 
research appears to show that the market is unfavorable 
for Co-60 in centers that would require shielding 
expansion for adoption (19).
The abstract “Quality of Life After I-125 Seeds Implantation 
in Patients with Advanced Malignant Tumor”, presented by 
Wang et al. found that seed implantation can improve the 
quality of life in patients with advanced malignant tumors (20). 
Analysis showed that 3 months after seed implantation, 
patients’ quality of life improved, but after 3 months, the 
patients’ quality of life declined and may be influenced by 
the tumor progression (Table 1) (20). Bajaj et al. discussed 
the successful reduction of treatment planning duration 
by 40% through optimization of clinical throughput, 
resulting in their HDR program having similar treatment 
time duration as compared to their LDR seed implant 
procedures (21).
Table 1 Changes on the quality of life after I-125 seed implantation in patients with advanced malignant tumor (20)
Items
Before the seeds 
implantation in 24 h
After the seeds 
implantation in 24 h
1 month after the seeds 
implantation
3 months after the 
seeds implantation
Total score in EORTCQLQ-C30 82.63±10.419 86.38±20.853 96.75±21.029 89.86±22.645
Total health performance in 1 week 4.10±1.708 4.26±1.624 4.8±1.389 4.11±1.491
Total quality of life in 1 week 4.14±1.719 4.26±1.712 4.83±1.403 3.94±1.893
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The utilization of brachytherapy is influenced by societal 
and economic factors as evidence from the presentations of 
researchers at the Annual Meeting. Although hurdles exist, 
such as the cost of implementation and training needed 
to run brachytherapy programs, it remains a clinically 
and cost-effective treatment option for patients with 
many disease site diagnoses. With economic and societal 
considerations effecting healthcare across the globe, the 
ABS and its membership remain dedicated to ensuring 
that researchers, physicians and hospital administrators 
are aware of the economic and patient related outcome 
data that encourage the implementation and utilization 
of a brachytherapy program within radiation oncology 
departments.
Conclusions
“The Value of Brachytherapy in Multidisciplinary Cancer Care” 
was evident at ABS’ 2017 Annual Meeting through the 
presentation of hundreds of abstracts that focused on the 
ways in which brachytherapy can positively impact clinical 
outcomes, overall survival and patient reported outcomes. 
Additionally, the value of brachytherapy was evident in the 
socioeconomic presentations from individuals across the 
globe. The ABS Annual Meeting featured novel findings of 
the development of MRI inclusion, algorithm and predictive 
programming progression for brachytherapy and the range 
of cancerous diseases which can benefit from the inclusion 
of brachytherapy during the course of care. Since 1978 the 
ABS and its membership have provided insight, rationale 
and research to clinicians on brachytherapy’s efficacy and 
they will continue to do so at the 2018 Annual Meeting, 
scheduled to be held June 07–09, 2018 in San Francisco, 
California.
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